This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain (SERENEATI)

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: November 27, 2008
Last updated: March 31, 2011
Last verified: March 2011

The primary objective of this study is to assess the efficacy of ataciguat versus placebo in reducing pain intensity in patients with neuropathic pain.

The secondary objective is to assess the safety and tolerability of ataciguat versus placebo.

Condition Intervention Phase
Pain Drug: ataciguat (HMR1766) Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Oral Ataciguat (HMR1766) 200 mg Administered Once Daily for 28 Days on Pain Reduction in Patients With Neuropathic Pain. A Randomized, Double-blind, Placebo-controlled, Cross-over Study

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Change in average daily pain intensity [ Time Frame: after 28-days treatment ]

Secondary Outcome Measures:
  • Responder rate [ Time Frame: after 28-days treatment ]
  • Rescue medication intake [ Time Frame: during 28-days treatment ]
  • Change in Neuropathic Pain Symptom Inventory (NPSI) [ Time Frame: after 28-days treatment ]

Enrollment: 62
Study Start Date: November 2008
Study Completion Date: September 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
First period: Ataciguat - Second period: Placebo
Drug: ataciguat (HMR1766)
oral administration 200mg once daily for 28 days
Drug: placebo
oral administration once daily for 28 days
Experimental: 2
First period: Placebo - Second period: Ataciguat
Drug: ataciguat (HMR1766)
oral administration 200mg once daily for 28 days
Drug: placebo
oral administration once daily for 28 days

Detailed Description:
This study consists of two consecutive 28 day treatment periods which are separated by a 2 week medication free period and a safety follow-up period of 2 weeks after the second treatment period.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with chronic neuropathic pain due to diabetic polyneuropathy or a nerve lesion following surgery. The pain must be present for more than 3 months.

Exclusion Criteria:

  • Presence or history of cancer within the past five years
  • Patients with a history of HIV infection
  • Patients with active hepatitis B or C
  • Patients with any pain other than the neuropathic pain of greater or equal severity
  • Patients with a diabetes mellitus for less than 6 months

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00799656

Sanofi-Aventis Administrative Office
Wien, Austria
Czech Republic
Sanofi-Aventis Administrative Office
Praha, Czech Republic
Sanofi-Aventis Administrative Office
Bucuresti, Romania
Sponsors and Collaborators
Principal Investigator: Hans-Goerg Kress, Professor Medizinische Universität / AKH Wien - Währinger Gürtel 18-20 - A-1090 Wien
  More Information

Responsible Party: ICD Study Director, sanofi-aventis Identifier: NCT00799656     History of Changes
Other Study ID Numbers: DFI10569
EudraCT 2008-001518-26
Study First Received: November 27, 2008
Last Updated: March 31, 2011

Keywords provided by Sanofi:
Diabetic neuropathy
painful pain

Additional relevant MeSH terms:
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms processed this record on September 21, 2017